Literature DB >> 9169564

In vitro and in vivo characterisation of nor-beta-CIT: a potential radioligand for visualisation of the serotonin transporter in the brain.

K A Bergström1, C Halldin, H Hall, C Lundkvist, N Ginovart, C G Swahn, L Farde.   

Abstract

Radiolabelled 2beta-carbomethoxy-3beta-(4-iodophenyl)tropane (beta-CIT) has been used in clinical studies for the imaging of dopamine and serotonin transporters with single-photon emission tomography (SPET). 2beta-Carbomethoxy-3beta-(4-iodophenyl)nortropane (nor-beta-CIT) is a des-methyl analogue of beta-CIT, which in vitro has tenfold higher affinity (IC50=0.36 nM) to the serotonin transporter than beta-CIT (IC50=4.2 nM). Nor-beta-CIT may thus be a useful radioligand for imaging of the serotonin transporter. In the present study iodine-125 and carbon-11 labelled nor-beta-CIT were prepared for in vitro autoradiographic studies on post-mortem human brain cryosections and for in vivo positron emission tomography (PET) studies in Cynomolgus monkeys. Whole hemisphere autoradiography with [125I]nor-beta-CIT demonstrated high binding in the striatum, the thalamus and cortical regions of the human brain. Addition of a high concentration (1 microM) of citalopram inhibited binding in the thalamus and the neocortex, but not in the striatum. In PET studies with [11C]nor-beta-CIT there was rapid uptake of radioactivity in the monkey brain (6% of injected dose at 15 min) and high accumulation of radioactivity in the striatum, thalamus and neocortex. Thalamus to cerebellum and cortex to cerebellum ratios were 2.5 and 1.8 at 60 min, respectively. The ratios obtained with [11C]nor-beta-CIT were 20%-40% higher than those previously obtained with [11C]beta-CIT. Radioactivity in the thalamus and the neocortex but not in the striatum was displaceable with citalopram (5 mg/kg). In conclusion, nor-beta-CIT binds to the serotonin transporter in the primate brain in vitro and in vivo and has potential for PET and SPET imaging of the serotonin transporter in human brain.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9169564     DOI: 10.1007/BF00841395

Source DB:  PubMed          Journal:  Eur J Nucl Med        ISSN: 0340-6997


  40 in total

1.  Autoradiography with saturation experiments of 11C-Ro 15-1788 binding to human brain sections.

Authors:  A Persson; R d'Argy; P G Gillberg; C Halldin; J E Litton; C G Swahn; G Sedvall
Journal:  J Neurosci Methods       Date:  1991-01       Impact factor: 2.390

2.  High- and low-affinity [3H]desipramine-binding sites in human postmortem brain tissue.

Authors:  I T Bäckström; J O Marcusson
Journal:  Neuropsychobiology       Date:  1990       Impact factor: 2.328

3.  Dexfenfluramine neurotoxicity in brains of non-human primates.

Authors:  G A Ricaurte; M E Molliver; M B Martello; J L Katz; M A Wilson; A L Martello
Journal:  Lancet       Date:  1991-12-14       Impact factor: 79.321

Review 4.  Clinical overview of serotonin reuptake inhibitors.

Authors:  K Rickels; E Schweizer
Journal:  J Clin Psychiatry       Date:  1990-12       Impact factor: 4.384

5.  3,4-Methylenedioxymethamphetamine and 3,4-methylenedioxyamphetamine destroy serotonin terminals in rat brain: quantification of neurodegeneration by measurement of [3H]paroxetine-labeled serotonin uptake sites.

Authors:  G Battaglia; S Y Yeh; E O'Hearn; M E Molliver; M J Kuhar; E B De Souza
Journal:  J Pharmacol Exp Ther       Date:  1987-09       Impact factor: 4.030

6.  Distribution of catecholamine uptake sites in human brain as determined by quantitative [3H] mazindol autoradiography.

Authors:  G A Donnan; S J Kaczmarczyk; G Paxinos; P J Chilco; R M Kalnins; D G Woodhouse; F A Mendelsohn
Journal:  J Comp Neurol       Date:  1991-02-15       Impact factor: 3.215

7.  [123I]-2 beta-carbomethoxy-3 beta-(4-iodophenyl)tropane: high-affinity SPECT radiotracer of monoamine reuptake sites in brain.

Authors:  J L Neumeyer; S Y Wang; R A Milius; R M Baldwin; Y Zea-Ponce; P B Hoffer; E Sybirska; M al-Tikriti; D S Charney; R T Malison
Journal:  J Med Chem       Date:  1991-10       Impact factor: 7.446

8.  Ritanserin, a 5-HT2 receptor antagonist, activates midbrain dopamine neurons by blocking serotonergic inhibition.

Authors:  L Ugedo; J Grenhoff; T H Svensson
Journal:  Psychopharmacology (Berl)       Date:  1989       Impact factor: 4.530

9.  High affinity [3H]paroxetine binding to serotonin uptake sites in human brain tissue.

Authors:  I Bäckström; M Bergström; J Marcusson
Journal:  Brain Res       Date:  1989-05-08       Impact factor: 3.252

10.  Presynaptic serotonergic dysfunction in patients with Alzheimer's disease.

Authors:  A M Palmer; P T Francis; J S Benton; N R Sims; D M Mann; D Neary; J S Snowden; D M Bowen
Journal:  J Neurochem       Date:  1987-01       Impact factor: 5.372

View more
  10 in total

1.  SPECT imaging with the serotonin transporter radiotracer [123I]p ZIENT in nonhuman primate brain.

Authors:  Kelly P Cosgrove; Julie K Staley; Ronald M Baldwin; Frederic Bois; Christophe Plisson; Mohammed S Al-Tikriti; John P Seibyl; Mark M Goodman; Gilles D Tamagnan
Journal:  Nucl Med Biol       Date:  2010-05-06       Impact factor: 2.408

Review 2.  Development of (18)F-labeled radiotracers for neuroreceptor imaging with positron emission tomography.

Authors:  Peter Brust; Jörg van den Hoff; Jörg Steinbach
Journal:  Neurosci Bull       Date:  2014-08-29       Impact factor: 5.203

3.  Fluorine-18 Radiolabeled PET Tracers for Imaging Monoamine Transporters: Dopamine, Serotonin, and Norepinephrine.

Authors:  Jeffrey S Stehouwer; Mark M Goodman
Journal:  PET Clin       Date:  2009-01

4.  5-Chloro-2-(2'-((dimethylamino)methyl)-4'-iodophenylthio)benzenamine: a new serotonin transporter ligand.

Authors:  Shunichi Oya; Seok-Rye Choi; Mei-Ping Kung; Hank F Kung
Journal:  Nucl Med Biol       Date:  2007-02       Impact factor: 2.408

5.  SPECT imaging of serotonin transporter binding in patients with generalized anxiety disorder.

Authors:  Eduard Maron; Jyrki T Kuikka; Kai Ulst; Jari Tiihonen; Veiko Vasar; Jakov Shlik
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2004-11-12       Impact factor: 5.270

6.  2-(2'-((dimethylamino)methyl)-4'-(fluoroalkoxy)-phenylthio)benzenamine derivatives as serotonin transporter imaging agents.

Authors:  Ajit K Parhi; Julie L Wang; Shunichi Oya; Seok-Rye Choi; Mei-Ping Kung; Hank F Kung
Journal:  J Med Chem       Date:  2007-12-04       Impact factor: 7.446

Review 7.  5-HT radioligands for human brain imaging with PET and SPECT.

Authors:  Louise M Paterson; Birgitte R Kornum; David J Nutt; Victor W Pike; Gitte M Knudsen
Journal:  Med Res Rev       Date:  2011-06-14       Impact factor: 12.944

Review 8.  The Emerging Role of SPECT Functional Neuroimaging in Schizophrenia and Depression.

Authors:  Anil Kalyoncu; Ali Saffet Gonul
Journal:  Front Psychiatry       Date:  2021-12-15       Impact factor: 4.157

9.  High correlation between in vivo [123I]β-CIT SPECT/CT imaging and post-mortem immunohistochemical findings in the evaluation of lesions induced by 6-OHDA in rats.

Authors:  Susanne Bäck; Mari Raki; Raimo K Tuominen; Atso Raasmaja; Kim Bergström; Pekka T Männistö
Journal:  EJNMMI Res       Date:  2013-06-10       Impact factor: 3.138

10.  Nuclear medicine in Finland.

Authors:  Kalevi Kairemo
Journal:  World J Nucl Med       Date:  2012-09
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.